Diagnosis and management of DNA mismatch repair-deficient colorectal cancer

Hematology/Oncology Clinics of North America

Volumn 29, Issue 1, 2015, Pages 29-41

  Stadler, Zsofia K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal cancer prognosis; Microsatellite instability; Mismatch repair deficiency

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; COLORECTAL TUMOR; DISEASE ASSOCIATION; GENETIC COUNSELING; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IN VITRO STUDY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHENOTYPE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; ADENOMA; ANIMAL; CARCINOMA; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MANAGEMENT; EARLY DIAGNOSIS; GENETICS; PROGNOSIS;

ADENOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MANAGEMENT; DNA MISMATCH REPAIR; EARLY DETECTION OF CANCER; FLUOROURACIL; HUMANS; MICROSATELLITE INSTABILITY; PROGNOSIS;

EID: 84919371820     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.09.008     Document Type: Review

References (54)

1. Ionov Y., Peinado M.A., Malkhosyan S., et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363:558-561.
2. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. JClin Oncol 2003, 21:1174-1179.
3. Thibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
4. Hampel H., Frankel W.L., Martin E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. JClin Oncol 2008, 26:5783-5788.
5. Hampel H., Frankel W., Panescu J., et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006, 66:7810-7817.
6. Fearon E.R., Vogelstein B. Agenetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
7. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature 1998, 396:643-649.
8. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instability in colorectal cancers. Nature 1997, 386:623-627.
9. Eshleman J.R., Casey J.R., Kochera G., et al. Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene 1998, 17:719-725.
10. Herman J.G., Umar A., Polyak K., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998, 95:6870-6875.
11. Kane M.F., Loda M., Gaida G.M., et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997, 57:808-811.
12. Jarvinen H.J., Aarnio M., Mustonen H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118:829-834.
13. Vasen H.F., Watson P., Mecklin J.P., et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116:1453-1456.
14. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. JNatl Cancer Inst 2004, 96:261-268.
15. Julie C., Tresallet C., Brouquet A., et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 2008, 103:2825-2835. [quiz: 2836].
16. Canard G., Lefevre J.H., Colas C., et al. Screening for Lynch syndrome in colorectal cancer: are we doing enough?. Ann Surg Oncol 2012, 19:809-816.
17. Leenen C.H., van Lier M.G., van Doorn H.C., et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer
18. Mvundura M., Grosse S.D., Hampel H., et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010, 12:93-104.
19. Ladabaum U., Wang G., Terdiman J., et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011, 155:69-79.
20. Vasen H.F., Mecklin J.P., Khan P.M., et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013, 62:812-823.
21. Evaluation of Genomic Applications in Practice and Prevention (EGAPP)WorkingGroup Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009, 11:35-41.
22. NCCN Genetic/Familial High-Risk Assessment: Colorectal (Version 2.2014). 2014. Available at: . Accessed November 3, 2014. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.
23. Cragun D., DeBate R.D., Hampel H., et al. Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. Genet Med 2014, 16(10):773-782.
24. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. ANational Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257.
25. Rodriguez-Bigas M.A., Boland C.R., Hamilton S.R., et al. ANational Cancer Institute Workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. JNatl Cancer Inst 1997, 89:1758-1762.
26. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. JMol Diagn 2008, 10:301-307.
27. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. JMol Diagn 2008, 10:293-300.
28. Oliveira C., Seruca R., Seixas M., et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003, 22:9192-9196.
29. Domingo E., Laiho P., Ollikainen M., et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. JMed Genet 2004, 41:664-668.
30. Deng G., Bell I., Crawley S., et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004, 10:191-195.
31. Bapat B., Lindor N.M., Baron J., et al. The association of tumor microsatellite instability phenotype with family history of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:967-975.
32. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. JClin Oncol 2005, 23:609-618.
33. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. NEngl J Med 2000, 342:69-77.
34. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. NEngl J Med 2003, 349:247-257.
35. Kim G.P., Colangelo L.H., Wieand H.S., et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. JClin Oncol 2007, 25:767-772.
36. Lamberti C., Lundin S., Bogdanow M., et al. Microsatellite instability did not predict individual survival ofunselected patients with colorectal cancer. Int J Colorectal Dis 2007, 22:145-152.
37. Carethers J.M., Chauhan D.P., Fink D., et al. Mismatch repair proficiency and invitro response to 5-fluorouracil. Gastroenterology 1999, 117:123-131.
38. Meyers M., Wagner M.W., Hwang H.S., et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001, 61:5193-5201.
39. Chen X.X., Lai M.D., Zhang Y.L., et al. Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. World J Gastroenterol 2002, 8:841-846.
40. van Triest B., Pinedo H.M., Blaauwgeers J.L., et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000, 6:1063-1072.
41. Iacopetta B., Kawakami K., Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?. Int J Clin Oncol 2008, 13:498-503.
42. Elsaleh H., Joseph D., Grieu F., et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000, 355:1745-1750.
43. Hemminki A., Mecklin J.P., Jarvinen H., et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000, 119:921-928.
44. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. JClin Oncol 2010, 28:3219-3226.
45. Tejpar S., Bosman F., Delorenzi M., et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC-3-EORTC 40993-SAKK 60/00 trial). JClin Oncol 2009, 27:a4001. [abstract].
46. Tejpar S., Saridaki Z., Delorenzi M., et al. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. JNatl Cancer Inst 2011, 103:841-844.
47. Roth AD, Tejpar S, Yan P, etal. Correlation of molecular markers in colon cancer with stage-specific prognosis: results of the translational study on the PETACC3-EORTC 40993-SAKK 60-00 trial. 2009 ASCO GI Cancer Symposium. San Francisco, CA, January 15-17, 2009. [abstract 288].
48. Sinicrope F.A., Foster N.R., Thibodeau S.N., et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. JNatl Cancer Inst 2011, 103:863-875.
49. Alemayehu A., Fridrichova I. The MRE11/RAD50/NBS1 complex destabilization in Lynch-syndrome patients. Eur J Hum Genet 2007, 15:922-929.
50. Wen Q., Scorah J., Phear G., et al. Amutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol Biol Cell 2008, 19:1693-1705.
51. Rodriguez R., Hansen L.T., Phear G., et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin Cancer Res 2008, 14:5476-5483.
52. Fallik D., Borrini F., Boige V., et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003, 63:5738-5744.
53. Bertagnolli M.M., Niedzwiecki D., Compton C.C., et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. JClin Oncol 2009, 27:1814-1821.
54. Koopman M., Kortman G.A., Mekenkamp L., et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009, 100:266-273.